Cox regression for PFS and OS among patients with DLBCL, transformed FL, and PMBCL (N = 167)
| Variable . | PFS, univariable . | PFS, multivariable (N = 150, 99 events) . | OS, univariable . | OS, multivariable (N = 150, 73 events) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age ≥60 years | 1.54 (1.03-2.28) | .034 | 1.84 (1.21-2.80) | .0044 | 1.33 (0.85-2.08) | .22 | 1.67 (1.03-2.71) | .037 |
| Female | 1.12 (0.76-1.65) | .56 | 1.35 (0.87-2.10) | .18 | ||||
| ECOG ≥2 | 1.84 (1.17-2.92) | .0089 | 1.04 (0.65-1.67) | .87 | 2.14 (1.28-3.56) | .0035 | 1.28 (0.75-2.19) | .36 |
| Histology (reference: DLBCL) | ||||||||
| Transformed FL | 1.00 (0.61-1.61) | .99 | 1.14 (0.66-1.97) | .63 | ||||
| PMBCL | 1.08 (0.54-2.15) | .84 | 1.42 (0.68-2.98) | .36 | ||||
| Double hit | 0.95 (0.61-1.49) | .82 | 1.21 (0.74-1.98) | .46 | ||||
| Primary refractory | 0.93 (0.63-1.37) | .72 | 1.25 (0.81-1.94) | .32 | ||||
| Previous lines of therapy ≥3 | 1.58 (1.07-2.33) | .021 | 1.79 (1.13-2.83) | .013 | ||||
| Previous transplant | 1.15 (0.68-1.92) | .61 | 0.61 (0.30-1.27) | .19 | ||||
| Advanced stage | 2.37 (1.44-3.95) | <.001 | 1.21 (0.66-2.24) | .54 | 2.20 (1.21-3.99) | .0094 | 1.29 (0.64-2.57) | .48 |
| Extranodal disease | 2.01 (1.26-3.20) | .0032 | 1.44 (0.87-2.38) | .16 | ||||
| CNS involvement | 2.54 (1.41-4.55) | .0018 | 2.74 (1.35-5.59) | .0055 | 2.35 (1.24-4.45) | .0091 | 2.29 (1.01-5.15) | .047 |
| Largest lesion maximum diameter, cm | 1.07 (1.03-1.10) | <.001 | 1.10 (1.06-1.14) | <.001 | ||||
| Largest lesion ≥5 cm | 1.32 (0.86-2.04) | .21 | 1.99 (1.15-3.42) | .014 | ||||
| Largest lesion ≥7.5 cm | 1.83 (1.21-2.75) | .0038 | 2.45 (1.51-3.96) | <.001 | ||||
| Largest lesion ≥10 cm | 2.46 (1.66-3.64) | <.001 | 1.63 (1.04-2.55) | .032 | 3.04 (1.93-4.77) | <.001 | 1.93 (1.11-3.34) | .019 |
| Maximum SUV ≥10 | 1.20 (0.71-2.02) | .51 | 1.83 (0.93-3.57) | .078 | ||||
| High preleukapheresis LDH | 1.65 (1.08-2.52) | .021 | 2.06 (1.22-3.48) | .0072 | ||||
| High preinfusion LDH | 3.37 (2.240-5.08) | <.001 | 2.57 (1.63-4.04) | <.001 | 4.88 (2.93-8.13) | <.001 | 3.29 (1.85-5.87) | <.001 |
| Bridging systemic therapy | 2.09 (1.42-3.09) | <.001 | 2.14 (1.38-3.33) | <.001 | ||||
| EQD2 (Gy) | 0.99 (0.97-1.00) | .087 | 0.99 (0.97-1.01) | .24 | ||||
| EQD2 ≥29.3 Gy (median) | 0.69 (0.47-1.01) | .058 | 0.69 (0.44-1.06) | .092 | ||||
| Br-RT to >1 site | 1.14 (0.71-1.83) | .60 | 1.40 (0.83-2.37) | .21 | ||||
| Comprehensive Br-RT | 0.34 (0.22-0.52) | <.001 | 0.38 (0.22-0.63) | <.001 | 0.30 (0.18-0.53) | <.001 | 0.45 (0.25-0.83) | .011 |
| Variable . | PFS, univariable . | PFS, multivariable (N = 150, 99 events) . | OS, univariable . | OS, multivariable (N = 150, 73 events) . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age ≥60 years | 1.54 (1.03-2.28) | .034 | 1.84 (1.21-2.80) | .0044 | 1.33 (0.85-2.08) | .22 | 1.67 (1.03-2.71) | .037 |
| Female | 1.12 (0.76-1.65) | .56 | 1.35 (0.87-2.10) | .18 | ||||
| ECOG ≥2 | 1.84 (1.17-2.92) | .0089 | 1.04 (0.65-1.67) | .87 | 2.14 (1.28-3.56) | .0035 | 1.28 (0.75-2.19) | .36 |
| Histology (reference: DLBCL) | ||||||||
| Transformed FL | 1.00 (0.61-1.61) | .99 | 1.14 (0.66-1.97) | .63 | ||||
| PMBCL | 1.08 (0.54-2.15) | .84 | 1.42 (0.68-2.98) | .36 | ||||
| Double hit | 0.95 (0.61-1.49) | .82 | 1.21 (0.74-1.98) | .46 | ||||
| Primary refractory | 0.93 (0.63-1.37) | .72 | 1.25 (0.81-1.94) | .32 | ||||
| Previous lines of therapy ≥3 | 1.58 (1.07-2.33) | .021 | 1.79 (1.13-2.83) | .013 | ||||
| Previous transplant | 1.15 (0.68-1.92) | .61 | 0.61 (0.30-1.27) | .19 | ||||
| Advanced stage | 2.37 (1.44-3.95) | <.001 | 1.21 (0.66-2.24) | .54 | 2.20 (1.21-3.99) | .0094 | 1.29 (0.64-2.57) | .48 |
| Extranodal disease | 2.01 (1.26-3.20) | .0032 | 1.44 (0.87-2.38) | .16 | ||||
| CNS involvement | 2.54 (1.41-4.55) | .0018 | 2.74 (1.35-5.59) | .0055 | 2.35 (1.24-4.45) | .0091 | 2.29 (1.01-5.15) | .047 |
| Largest lesion maximum diameter, cm | 1.07 (1.03-1.10) | <.001 | 1.10 (1.06-1.14) | <.001 | ||||
| Largest lesion ≥5 cm | 1.32 (0.86-2.04) | .21 | 1.99 (1.15-3.42) | .014 | ||||
| Largest lesion ≥7.5 cm | 1.83 (1.21-2.75) | .0038 | 2.45 (1.51-3.96) | <.001 | ||||
| Largest lesion ≥10 cm | 2.46 (1.66-3.64) | <.001 | 1.63 (1.04-2.55) | .032 | 3.04 (1.93-4.77) | <.001 | 1.93 (1.11-3.34) | .019 |
| Maximum SUV ≥10 | 1.20 (0.71-2.02) | .51 | 1.83 (0.93-3.57) | .078 | ||||
| High preleukapheresis LDH | 1.65 (1.08-2.52) | .021 | 2.06 (1.22-3.48) | .0072 | ||||
| High preinfusion LDH | 3.37 (2.240-5.08) | <.001 | 2.57 (1.63-4.04) | <.001 | 4.88 (2.93-8.13) | <.001 | 3.29 (1.85-5.87) | <.001 |
| Bridging systemic therapy | 2.09 (1.42-3.09) | <.001 | 2.14 (1.38-3.33) | <.001 | ||||
| EQD2 (Gy) | 0.99 (0.97-1.00) | .087 | 0.99 (0.97-1.01) | .24 | ||||
| EQD2 ≥29.3 Gy (median) | 0.69 (0.47-1.01) | .058 | 0.69 (0.44-1.06) | .092 | ||||
| Br-RT to >1 site | 1.14 (0.71-1.83) | .60 | 1.40 (0.83-2.37) | .21 | ||||
| Comprehensive Br-RT | 0.34 (0.22-0.52) | <.001 | 0.38 (0.22-0.63) | <.001 | 0.30 (0.18-0.53) | <.001 | 0.45 (0.25-0.83) | .011 |
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; PMBCL, primary mediastinal B-cell lymphoma.
Boldface indicates significant P values <0.05.